Reversible, p16-mediated cell cycle arrest as protection from chemotherapy

Cancer Research

Volumn 56, Issue 14, 1996, Pages 3199-3202

  Stone, Steven ^a   Dayananth, Priya ^a   Kamb, Alexander ^a  

^a Myriad Genetics Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; METHOTREXATE; VINBLASTINE;

ARTICLE; CANCER THERAPY; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL VIABILITY; FLOW CYTOMETRY; GENOTYPE; GROWTH REGULATION; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; CELL CYCLE; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DRUG ADMINISTRATION SCHEDULE; HUMANS; METHOTREXATE; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0029982829     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Pardee, A. B., and James, L. J. Selective killing of transformed baby kidney (BHK) cells Proc. Natl. Acad. Sci. USA, 72: 4994-4998, 1975.
2. Hartwell, L. H., and Kastan, M. B. Cell cycle control and cancer. Science (Washington DC), 266: 1821-1828, 1994.
3. Kohn, K W., Jackman, J., and O'Connor, P. M. Cell cycle control and cancer chemotherapy. J. Cell. Biochem., 54 440-452, 1994.
4. Darzynkiewicz, Z. Apoptosis in anticancer strategies: modulation of cell cycle or differentiation. J. Cell. Biochem , 58: 151-159, 1995.
5. INK4. Science (Washington DC), 267: 249-252, 1995.
6. Lukas, J., Parry, D., Aagaard, L , Mann, D. J., Bartkova, J., Strauss, M., Peters, G., and Bartek, J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (Lond.), 375: 503-506, 1995
7. Kamb, A. Cell-cycle regulators and cancer. Trends Genet., 11: 136-140, 1995.
8. Cairns, P., Polascik, T. J., Eby, Y., Tokino, K., Califano, J., Merlo, A., Mao, L., Herath, J., Jenkins, R., Westra, W , Rutter, J. L., Buckler, A , Gabrielson, E , Tockman, M., Cho, K. R., Hedrick, L., Bova, G. S., Isaacs, W., Koch, W., Schwab, D., and Sidransky, D. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat. Genet., 11: 210-212, 1995.
9. Kozak, M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell, 44: 283-292, 1986.
10. Pratt, W. B , Ruddon, R. W , Ensminger, W. D., and Maybaum, J The Anticancer Drugs, pp. 75-79. New York Oxford University Press, 1994.
11. Pratt, W. B., Ruddon, R W , Ensminger, W. D , and Maybaum, J. The Anticancer Drugs, pp. 188-190 New York: Oxford University Press, 1994.
12. Pratt, W B., Ruddon, R W , Ensminger, W D., and Maybaum, J The Anticancer Drugs, pp 134-135. New York: Oxford University Press, 1994.
13. Serrano, M., Hannon, G. J , and Beach, D A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK 4 Nature (Lond.), 366: 704-707, 1993.
14. Li, Y., Nichols, M. A., Shay, J. W., and Xiong, Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb Cancer Res , 54: 6078-6082, 1994.
15. INK4 Cancer Res., 54: 5816-5820, 1994.
16. INK4/MTS1 tumour suppressor gene product. EMBO J., 14: 503-511, 1995
17. Stone, S , Jiang, P , Dayananth, P., Tavtigian, S. V , Katcher, H , Parry, D., Peters, G., and Kamb, A. Complex structure and regulation of the p16 (MTS1) locus Cancer Res , 55 2988-2994, 1995.